NCT07312422RecruitingPhase 1/2
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
An Open-label, Single-center, Single-arm Study to Evaluate the Efficacy and Safety of Low-dose Radiation Therapy Combined With Pultelimab and Standard Treatment in Patients With Advanced Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 26 Jan 2026
Brief summary (registry, in English)
To investigate the activating effect of local lesion low-dose radiotherapy (2Gy) on the tumor immune microenvironment, and the efficacy, safety, and feasibility of its combination with pembrolizumab and standard therapy in patients with advanced pancreatic cancer. Concurrently, to preliminarily establish an efficacy prediction model for the early identification of patient populations who would benefit from the treatment, thereby providing a theoretical foundation for the implementation of precision medicine.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 10 Dec 2025
- Start date
- 30 Sept 2025
- Primary completion date
- 30 Apr 2026
- Lead sponsor
- Zhejiang Provincial People's Hospital
- Diseases
- Pancreatic cancer
- NCT number
- NCT07312422
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 10
- From 30 Sept 2025 to the primary completion date, 30 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous history of radiotherapy;
Other illness
- Uncontrolled chronic infectious or non-infectious diseases, including but not limited to: medication-refractory heart failure, poorly controlled hypertension, etc.;
- Active or clinically uncontrolled severe infections;
- History of psychoactive drug abuse that cannot be abstained from, or patients with psychiatric disorders;
- Other conditions deemed by the investigator as potentially affecting the conduct of the clinical study or the interpretation of study results.
Other
- Pregnant or lactating women, or patients of childbearing potential who are unwilling or unable to adopt effective contraceptive measures;
Who the study is looking for
- Age ≥ 18 years, regardless of gender;
- ECOG score of 0 to 1;
- Patients with histologically or cytologically confirmed pancreatic malignancy;
- No prior treatment with PD-1 or PD-L1 inhibitors;
- Presence of a radiotherapeutically eligible target lesion (excluding bone metastases);
- Subjects voluntarily participate in the study and provide signed informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhejiang Provincial People's Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.